Calciphylaxis: Treatment and outlook-CME part II.

Jonathan Rick, Renajd Rrapi, Sidharth Chand, Michi M Shinohara, Lindsay Strowd, Helena B Pasieka, Robert Micheletti, Daniela Kroshinsky, Alex G Ortega-Loayza

Journal: Journal of the American Academy of Dermatology 2022;86(5):985-992

PMID: 35202773

Full Text on Elsevier Science View on PubMed

Abstract

Calciphylaxis is a rare and devastating condition with important systemic ramifications. This second-part of our CME aims to educate the practicing dermatologist on the current standard of care once a diagnosis of calciphylaxis is confirmed or highly suspected. The key pathologic findings, as well as the role and limitations of biopsy, are reviewed. We aim to guide readers through the complex hospitalization and posthospitalization management of these medically vulnerable patients. Collaboration with other specialists will be discussed. Experimental and developing treatments are discussed, and the outlook of the condition is reported.

Address: Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.; Department of Dermatology, Harvard Medical School, Cambridge, Massachusetts.; Division of Dermatology, University of Washington, Seattle, Washington.; Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina.; Department of Dermatology, Georgetown University School of Medicine, Washington, District of Columbia; Department of Dermatology, Uniformed Services University School of Medicine, Bethesda, Maryland.; Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.; Department of Dermatology, Oregon Health and Sciences University, Portland, Oregon. Electronic address: [email protected].

DOI: 10.1016/j.jaad.2021.10.063

Link outs

Free resources

Medical:

https://medlineplus.gov/kidneyfailure.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Calciphylaxis, Female, Humans, Kidney Failure, Chronic, Male, Thiosulfates